New pharmacological therapies for the treatment of benign prostatic hyperplasia: a systematic review
DOI:
https://doi.org/10.63688/531xeh49Keywords:
Benign prostatic hyperplasia, Pharmacotherapy, Urinary symptomsAbstract
Introduction: Benign prostatic hyperplasia is common in men and represents an important cause of lower urinary tract symptoms. Pharmacological strategies seek to improve symptoms and expand available therapeutic options.
Methodology: A descriptive, qualitative narrative review was conducted following PRISMA 2020 recommendations for evidence identification, selection, and synthesis. PubMed, Scopus, and SciELO were searched for publications between 2021 and 2026 in Spanish and English. Studies addressing pharmacological therapies for benign prostatic hyperplasia were included.
Results: A total of 115 records were identified, and after duplicate removal and selection criteria were applied, 9 articles were included in the synthesis. Studies evaluated drug combinations, dose adjustments, emerging alternatives, and treatments targeting urinary symptoms. Improvements were observed in symptoms, urinary flow, and postvoid residual volume, although some interventions did not demonstrate significant benefits.
Conclusions: The evidence shows an evolution toward combined and individualized therapies. Some emerging alternatives require longer follow-up to confirm their clinical utility.
Downloads
References
AbdelRazek, M., Abolyosr, A., Mhammed, O., Fathi, A., Talaat, M., & Hassan, A. (2022). Prospective comparison of tadalafil 5 mg alone, silodosin 8 mg alone, and the combination of both in treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. World Journal of Urology, 40(8), 2063–2070. https://doi.org/10.1007/s00345-022-04071-7
Aroca Mantilla, A. S. (2026). Hiperplasia prostática benigna. Diagnóstico, tratamiento y nuevas estrategias terapéuticas: Revisión narrativa. Mediciencias UTA, 10(1), 32–43. https://doi.org/10.31243/mdc.v10i1.3106.2026
Astudillo Sánchez, M. V., Reinoso Martínez, L. A., Veloz Espinoza, M. B., & Soria Barrionuevo, N. E. (2024). Hipertrofia prostática, diagnóstico por imagen y actualización en el tratamiento clínico/quirúrgico. RECIAMUC, 8(2), 444–450. https://doi.org/10.26820/reciamuc/8.(2).abril.2024.444-450
Bauer, S. R., Kenfield, S. A., Oni-Orisan, A., Shlipak, M. G., Lu, K., Rios, N., Pearce, R., Harmon, J., McCulloch, C. E., Huang, L., Steinman, M. A., & Breyer, B. N. (2026). Tamsulosin deprescribing for lower urinary tract symptoms in older men: A randomized clinical trial. JAMA Network Open, 9(7), Article e2621639. https://doi.org/10.1001/jamanetworkopen.2026.21639
El Eysami, M. (2025). Introducción, epidemiología, etiología y fisiopatología de la hiperplasia prostática benigna. Revista Venezolana de Urología, 60(1). https://doi.org/10.70068/REVSOVEURO.2025.60.1.2
Kim, Y. H., & Je, N. K. (2025). Prescription trends of initial pharmacotherapy for benign prostatic hyperplasia among treatment-naïve patients in South Korea: A retrospective analysis. LUTS: Lower Urinary Tract Symptoms, 17(5), Article e70030. https://doi.org/10.1111/luts.70030
Lee, S. W., Lee, S. H., Kim, J. H., Noh, J. H., Lee, J. H., Ha, U.-S., Oh, C. Y., Kang, T. W., Lee, K. S., Lee, S., Han, D. H., Han, J. H., Song, S. H., Park, H. J., Chung, B. H., Min, G. E., Jeong, I. G., Moon, K. H., Kim, W. T., . . . Kim, C.-S. (2026). Combined therapy with dutasteride and tadalafil vs dutasteride or tadalafil monotherapy in benign prostatic hyperplasia: A randomised phase III trial. BJU International, 137(4), 698–707. https://doi.org/10.1111/bju.70163
Osman, T., Elawady, H., Fawaz, K., Shabayek, M., Essam, M. D., Osman, D., & ElSaeed, K. O. (2024). Evaluation of tamsulosin 0.4 mg versus 0.8 mg in management of lower urinary tract symptoms due to benign prostatic enlargement. International Urology and Nephrology, 56(6), 1811–1816. https://doi.org/10.1007/s11255-023-03912-7
Patiño Camacho, V. E., Albán Tapia, J. P., Quezada Escandón, R. D., Rojas Romero, A. R., Chontasi Changoluisa, Á. C., Burgos Palma, M. L., Mora Aldas, Q. G., & Jalil Moreno, S. J. (2025). Diagnóstico y manejo de la hiperplasia prostática benigna: Avances en técnicas quirúrgicas. Ibero-American Journal of Health Science Research, 5(2), 18–25. https://doi.org/10.56183/iberojhr.v5i2.766
Rastrelli, G., Cipriani, S., Lotti, F., Cellai, I., Comeglio, P., Filippi, S., Boddi, V., Della Camera, P. A., Santi, R., Boni, L., Nesi, G., Serni, S., Gacci, M., Maggi, M., & Vignozzi, L. (2022). Testosterone does not affect lower urinary tract symptoms while improving markers of prostatitis in men with benign prostatic hyperplasia: A randomized clinical trial. Journal of Endocrinological Investigation, 45(7), 1413–1425. https://doi.org/10.1007/s40618-022-01776-9
Ratajski, J., Ciechan, K., Jędrzejczyk, P., Kaminski, T. W., Uciechowski, P., & Ząbkowski, T. (2025). Comparative effectiveness and safety of finasteride and dutasteride in the treatment of benign prostatic hyperplasia: A real-world retrospective study. Medicina, 61(11), Article 1944. https://doi.org/10.3390/medicina61111944
Widerstrom Isea, H., Cañete García, S., Venegas Varas, F., Gardeweg Páez, V., Lavín Ferrada, P., & Madriaza Valenzuela, V. (2024). Benign prostatic hyperplasia: A quantitative study about Chilean epidemiology. Revista Confluencia, 7. https://doi.org/10.52611/confluencia.2024.1115
Wei, Y., Hay, J. W., Hay, A. R., & Suen, S.-C. (2022). Fexapotide triflutate vs oral pharmacotherapy as initial therapy for moderate-to-severe benign prostate hyperplasia patients: A cost-effectiveness analysis. BMC Urology, 22, Article 76. https://doi.org/10.1186/s12894-022-01025-4
Yang, P., Wang, H., Lv, J., & Wang, J. (2026). Xia Li Qi capsules improve symptoms and urodynamic parameters in patients with benign prostatic hyperplasia: A randomised controlled trial with evidence of p38–JAK/STAT axis inhibition. Archivos Españoles de Urología, 79(6), 992–1003. https://doi.org/10.56434/j.arch.esp.urol.20267906.115
Yoshida, M., Nishino, Y., Nagae, H., Kato, S., Sakamoto, S., Hojo, M., Miyauchi, T., Kageyama, S., Takahashi, S., Kuroda, H., Mori, N., Kasagi, Y., Masunaga, K., Nabeshima, Y., Nomiya, M., Iwashita, K., Miyamae, K., Otani, M., Kawahara, K., . . . Haga, N. (2026). Efficacy and safety of vibegron add-on therapy for persistent overactive bladder symptoms in benign prostatic hyperplasia patients with α1-blocker treatment: A multi-center prospective randomized controlled study (VATON Study). LUTS: Lower Urinary Tract Symptoms, 18(2), Article e70053. https://doi.org/10.1111/luts.70053
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Joel Sebastian Chango Yosa, Allyson Madeline Barrera Vásquez, Jorge Luis Guzmán León, Daniel Andrés Andrade Párraga, Analía Lorena Velásquez Menoscal (Autor/a)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Los artículos publicados en la revista se distribuyen bajo la licencia Creative Commons Atribución 4.0 Internacional (CC BY 4.0). Esta licencia permite a terceros descargar, copiar, distribuir, adaptar y reutilizar una obra, incluso con fines comerciales, siempre que se otorgue el crédito adecuado al autor original.
